Literature DB >> 24474086

Elevated plasma CL-K1 level is associated with a risk of developing disseminated intravascular coagulation (DIC).

Kazue Takahashi1, Katsuki Ohtani, Mykol Larvie, Patience Moyo, Lorencia Chigweshe, Elizabeth M Van Cott, Nobutaka Wakamiya.   

Abstract

Collectin kidney 1 (CL-K1) is a recently identified collectin that is synthesized in most organs and circulates in blood. CL-K1 is an innate immune molecule that may play a significant role in host defense. As some collectins also play a role in coagulation, we hypothesized that an effect of CL-K1 may be apparent in disseminated intravascular coagulation (DIC), a gross derangement of the coagulation system that occurs in the setting of profound activation of the innate immune system. DIC is a grave medical condition with a high incidence of multiple organ failure and high mortality and yet there are no reliable biomarkers or risk factors. In our present study, we measured plasma CL-K1 concentration in a total of 659 specimens, including 549 DIC patients, 82 non-DIC patients and 27 healthy volunteers. The median plasma CL-K1 levels in these cohorts were 424, 238 and 245 ng/ml, respectively, with no significant difference in the latter two groups. The incidence of elevated plasma CL-K1 was significantly higher in the DIC patients compared to the non-DIC patients, resulting in an odds ratio of 1.929 (confidence interval 1.041-3.866). Infection, renal diseases, respiratory diseases, and cardiac diseases were more frequently observed in the DIC group than in the non-DIC group. In the DIC group, vascular diseases were associated with elevated plasma CL-K1 levels while age and acute illness had little effect on plasma CL-K1 levels. Independent of DIC, elevated plasma CL-K1 levels were associated with respiratory disease and coagulation disorders. These results suggest that specific diseases may affect CL-K1 synthesis in an organ dependent manner and that elevated plasma CL-K1 levels are associated with the presence of DIC. Further investigations in cohorts of patients are warranted. We propose that elevated plasma CL-K1 may be a new useful risk factor and possibly biomarker for the prediction of developing DIC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24474086      PMCID: PMC6362979          DOI: 10.1007/s11239-013-1042-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis.

Authors:  C Downey; R Kazmi; C H Toh
Journal:  Thromb Haemost       Date:  1998-07       Impact factor: 5.249

Review 2.  Disseminated intravascular coagulation in patients with multiple organ failure of non-septic origin.

Authors:  J A Penner
Journal:  Semin Thromb Hemost       Date:  1998       Impact factor: 4.180

Review 3.  The role of the mannose-binding lectin in innate immunity.

Authors:  Kazue Takahashi; R Alan B Ezekowitz
Journal:  Clin Infect Dis       Date:  2005-11-15       Impact factor: 9.079

Review 4.  Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins.

Authors:  Steffen Thiel
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

5.  Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation.

Authors:  Cheng Hock Toh; John Samis; Colin Downey; John Walker; Lev Becker; Nicole Brufatto; Liliana Tejidor; Greg Jones; Wim Houdijk; Alan Giles; Marlys Koschinsky; Larry O Ticknor; Ray Paton; Richard Wenstone; Michael Nesheim
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 6.  Mannose-binding lectin deficiency--revisited.

Authors:  Peter Garred; Flemming Larsen; Hans O Madsen; Claus Koch
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

7.  Differential substrate and inhibitor profiles for human MASP-1 and MASP-2.

Authors:  Julia S Presanis; Krishnan Hajela; Géza Ambrus; Péter Gál; Robert B Sim
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

8.  Lessons learned from murine models of mannose-binding lectin deficiency.

Authors:  Kazue Takahashi
Journal:  Biochem Soc Trans       Date:  2008-12       Impact factor: 5.407

9.  An enzyme-linked immunosorbent assay (ELISA) for quantification of human collectin 11 (CL-11, CL-K1).

Authors:  L Selman; M L Henriksen; J Brandt; Y Palarasah; A Waters; P L Beales; U Holmskov; T J D Jørgensen; C Nielsen; K Skjodt; S Hansen
Journal:  J Immunol Methods       Date:  2011-10-20       Impact factor: 2.303

10.  Mannose-binding lectin binds to amyloid β protein and modulates inflammation.

Authors:  Mykol Larvie; Timothy Shoup; Wei-Chuan Chang; Lorencia Chigweshe; Kevan Hartshorn; Mitchell R White; Gregory L Stahl; David R Elmaleh; Kazue Takahashi
Journal:  J Biomed Biotechnol       Date:  2012-03-27
View more
  12 in total

1.  Collectin liver 1 and collectin kidney 1 and other complement-associated pattern recognition molecules in systemic lupus erythematosus.

Authors:  A Troldborg; S Thiel; L Jensen; S Hansen; M J Laska; B Deleuran; J C Jensenius; K Stengaard-Pedersen
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

2.  Collectin Kidney 1 Plays an Important Role in Innate Immunity against Streptococcus pneumoniae Infection.

Authors:  Insu Hwang; Kenichiro Mori; Katsuki Ohtani; Yasuyuki Matsuda; Nitai Roy; YounUck Kim; Yasuhiko Suzuki; Nobutaka Wakamiya
Journal:  J Innate Immun       Date:  2017-01-10       Impact factor: 7.349

Review 3.  Complement Recognition Pathways in Renal Transplantation.

Authors:  Christopher L Nauser; Conrad A Farrar; Steven H Sacks
Journal:  J Am Soc Nephrol       Date:  2017-06-29       Impact factor: 10.121

4.  Collectin-11 detects stress-induced L-fucose pattern to trigger renal epithelial injury.

Authors:  Conrad A Farrar; David Tran; Ke Li; Weiju Wu; Qi Peng; Wilhelm Schwaeble; Wuding Zhou; Steven H Sacks
Journal:  J Clin Invest       Date:  2016-04-18       Impact factor: 14.808

5.  Lectin complement protein Collectin 11 (CL-K1) and susceptibility to urinary schistosomiasis.

Authors:  Justin S Antony; Olusola Ojurongbe; Peter G Kremsner; Thirumalaisamy P Velavan
Journal:  PLoS Negl Trop Dis       Date:  2015-03-25

6.  Genetic variation of COLEC10 and COLEC11 and association with serum levels of collectin liver 1 (CL-L1) and collectin kidney 1 (CL-K1).

Authors:  Rafael Bayarri-Olmos; Soren Hansen; Maiken Lumby Henriksen; Line Storm; Steffen Thiel; Peter Garred; Lea Munthe-Fog
Journal:  PLoS One       Date:  2015-02-24       Impact factor: 3.240

Review 7.  Rationale for targeting complement in COVID-19.

Authors:  Anastasia Polycarpou; Mark Howard; Conrad A Farrar; Roseanna Greenlaw; Giorgia Fanelli; Russell Wallis; Linda S Klavinskis; Steven Sacks
Journal:  EMBO Mol Med       Date:  2020-07-12       Impact factor: 12.137

8.  Development of a Quantitative Assay for the Characterization of Human Collectin-11 (CL-11, CL-K1).

Authors:  Rafael Bayarri-Olmos; Nikolaj Kirketerp-Moller; Laura Pérez-Alós; Karsten Skjodt; Mikkel-Ole Skjoedt; Peter Garred
Journal:  Front Immunol       Date:  2018-09-28       Impact factor: 7.561

9.  Molecular basis of sugar recognition by collectin-K1 and the effects of mutations associated with 3MC syndrome.

Authors:  Umakhanth Venkatraman Girija; Christopher M Furze; Alexandre R Gingras; Takayuki Yoshizaki; Katsuki Ohtani; Jamie E Marshall; A Katrine Wallis; Wilhelm J Schwaeble; Mohammed El-Mezgueldi; Daniel A Mitchell; Peter C E Moody; Nobutaka Wakamiya; Russell Wallis
Journal:  BMC Biol       Date:  2015-04-17       Impact factor: 7.431

10.  iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy.

Authors:  Hongmei Lu; Shaodong Deng; Minghui Zheng; Kunhua Hu
Journal:  Clin Proteomics       Date:  2019-07-31       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.